Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Swati Elchuri

Pediatric Endocrinology Ventura, CA Medical Doctor

NPI 1750569133 CMS profile 641150

300 Hillmont Ave Ste 302, Ventura, CA 93003

Open in the dashboard

General payments

$210,325

288 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Swati Elchuri of Ventura, CA is reported in the CMS Open Payments database as having received $210,325 across 288 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78,978 102
2024 General $95,680 107
2023 General $34,884 50
2022 General $386 11
2021 General $143 5
2020 General $99 5
2019 General $155 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Swati Elchuri
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Swati Elchuri were reported at $78,978. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Swati Elchuri Pediatric Endocrinology median Middle half National median
2019 $155 $196 $68–$845 $163
2020 $99 $124 $37–$722 $114
2021 $143 $134 $35–$691 $132
2022 $386 $177 $47–$726 $149
2023 $34,884 $236 $75–$887 $160
2024 $95,680 $259 $91–$979 $164
2025 $78,978 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $194,246 165 payments
  2. Genzyme Corporation $7,038 3 payments
  3. Insulet Corporation $6,548 20 payments
  4. Medtronic, Inc. $462 11 payments
  5. Dexcom, Inc. $419 18 payments
  6. Ascendis Pharma, Inc. $348 15 payments
  7. Novo Nordisk Inc $270 8 payments
  8. Tolmar, Inc. $169 7 payments
  9. Amphastar Pharmaceuticals, Inc. $149 8 payments
  10. AbbVie, Inc. $111 6 payments
  11. Other $565 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $171,392 60 payments
  2. Travel and Lodging $31,266 61 payments
  3. Food and Beverage $7,667 167 payments
Products named General payments · program years 2019–2025
  1. TZIELD $188,484 162 payments
  2. Omnipod $6,516 19 payments
  3. Dexcom G6 Transmitter $394 17 payments
  4. SKYTROFA $348 15 payments
  5. Sogroya $170 7 payments
  6. MINIMED 770G $159 3 payments
  7. FENSOLVI $130 5 payments
  8. MINIMED 780G $122 4 payments
  9. Wegovy $100 1 payment
  10. INPEN SMART INSULIN DELIVERY SYSTEM $92 2 payments
  11. Other $849 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

288 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record